REDWOOD CITY, Calif.,
July 20, 2017 /PRNewswire/
-- Genomic Health, Inc. (NASDAQ: GHDX) today
announced that the company will host a conference call and webcast
on Tuesday, August 1 at 4:30 p.m. Eastern Time to
discuss its second quarter 2017 financial results. The call
and webcast will follow the release of the second quarter financial
results after market close.
Conference Call Details
To access the live conference call on August
1 at 4:30 p.m. Eastern Time via phone, please dial
(877) 303-7208 from the United States and Canada, or
+1 (224) 357-2389 internationally. The conference call ID is
47057890. Please dial in approximately ten minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
presentation, go to the Investor Relations section of the company's
web site at http://investor.genomichealth.com. Please connect to
the web site at least 15 minutes prior to the presentation to allow
for any software download that may be necessary.
About Genomic Health
Genomic Health, Inc.
(NASDAQ: GHDX) is the world's leading provider of genomic-based
diagnostic tests that help optimize cancer care, including
addressing the overtreatment of the disease, one of the greatest
issues in healthcare today. With its Oncotype
IQ® Genomic Intelligence Platform, the company is
applying its world-class scientific and commercial expertise and
infrastructure to lead the translation of clinical and genomic big
data into actionable results for treatment planning throughout the
cancer patient journey, from diagnosis to treatment selection and
monitoring. The Oncotype IQ portfolio of genomic tests and services
currently consists of the company's flagship line of Oncotype DX
gene expression tests that have been used to guide treatment
decisions for more than 750,000 cancer patients
worldwide. Genomic Health is expanding its test portfolio
to include additional liquid- and tissue-based tests, including the
recently launched Oncotype SEQ® Liquid
Select™ test. The company is based in Redwood
City, California, with international headquarters
in Geneva, Switzerland. For more information, please
visit, www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of
future performance. These risks and uncertainties are set forth in
our filings with the Securities and Exchange Commission, including
our most recent report on Form 10-Q for the quarter ended
March 31, 2017. These forward-looking
statements speak only as of the date hereof. Genomic Health
disclaims any obligation to update these forward-looking
statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX,
Recurrence Score, DCIS Score, Oncotype SEQ, Liquid Select, Genomic
Prostate Score, Oncotype DX AR-V7 Nucleus Detect and Oncotype IQ
are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their
respective owners.
GHDX-F
View original content with
multimedia:http://www.prnewswire.com/news-releases/genomic-health-to-announce-second-quarter-2017-financial-results-and-host-conference-call-on-tuesday-august-1-2017-300491289.html
SOURCE Genomic Health, Inc.